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E-mail address: hung1228@ms10.hinet.net (W.-C.Our previous study demonstrates that HER-2/Neu oncogene inhibits a matrix metalloproteinase
inhibitor and tumor metastasis suppressor RECK to promote metastasis. Conversely, the effect of
RECK on the oncogenic function of HER-2/Neu is unknown. Ectopic expression of RECK in 293T cells
and HER-2/Neu-overexpressing breast cancer cells shows that RECK and HER-2/Neu are co-localized
and these two proteins can be co-immunoprecipitated. RECK inhibits HER-2/Neu receptor dimeriza-
tion and autophosphorylation, which causes reduction of ERK and AKT kinase activity and down-
regulation of HER-2/Neu target genes. RECK expression is reduced in 58.8% of breast cancer tissues
and is associated with lymph node invasion supporting its anti-metastatic role. Collectively, we pro-
vide the ﬁrst evidence that RECK can negatively regulate oncogenic activity of HER-2/Neu by inhib-
iting receptor dimerization.
Structured summary:
HER-2/Neu physically interacts with HER-2/Neu by blue native page (View interaction)
HER-2/Neu physically interacts with RECK by coimmunoprecipitation (View interaction)
HER-2/Neu and RECK colocalize by ﬂuorescence microscopy (View Interaction 1, 2)
HER-2/Neu physically interacts with RECK by anti bait coimmunoprecipitation (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The RECK gene was isolated as a transformation suppressor
gene by using an expression cloning strategy designed to identify
human cDNA inducing ﬂat reversion in a v-Ki-ras-transformed
NIH/3T3 cell line [1]. This gene encodes a membrane glycoprotein
that may inhibit tumor metastasis and angiogenesis by negatively
regulating matrix metalloproteinase (MMP) activity [2]. While
RECK mRNA is expressed in most of normal human tissues and
untransformed cells, it is undetectable in many tumor cell lines.
Additionally, clinical studies also indicate that patients with high
RECK expression in tumor tissues show better survival and such
tumors are less invasive [3,4]. These results strongly suggest that
RECK is a novel suppressor gene for metastasis and angiogenesis.chemical Societies. Published by E
ciences, National Sun Yat-Sen
wan. Fax: +886 7 5250197.
Hung).We have addressed the transcriptional regulation of RECK gene
in various types of human cancer and ﬁnd that RECK is a molecular
target for HER-2/Neu oncogene and Epstein-Barr virus oncoprotein
latent membrane protein 1 [5,6]. Our results suggest the involve-
ment of epigenetic mechanism in the control of RECK expression
by oncogenes [7,8]. In addition, a recent study demonstrates that
miRNAs also participate in the modulation of RECK expression in
cancer cells [9].
Although the genetic regulation of RECK has been well charac-
terized, the biological function of RECK protein is not fully under-
stood. Ours and others results have clearly demonstrated the
MMP-inhibitory function of RECK protein [1,10]. Because RECK is
a GPI-anchored membrane protein, a potential role for RECK in
the modulation of signal transduction via interaction with cell sur-
face proteins is highly suggested. However, RECK has never been
shown to interact with growth factor receptors (like HER-2/Neu).
In this study, we address this issue and try to clarify whether RECK
can affect the oncogenic function of HER-2/Neu.lsevier B.V. All rights reserved.
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2.1. Cell lines and experimental materials
The human breast carcinoma cell line SKBR3 was maintained in
McCoys 5A with 10% of fetal bovine serum (FBS), and human
embryonic kidney 293T cells was cultured in DMEM-F12 contain-
ing 10% FBS. Human RECK cDNA and HER-2/Neu were kindly
provided by Dr. Noda M. (Kyoto University, Kyoto, Japan) [2] and
Dr. Hung M.C. (MD Anderson Cancer Center, Texas, USA) [11],
respectively.
2.2. Immunoﬂuorescent staining
Cells were transfected with EGFP-tagged HER-2/Neu or His-
tagged RECK expression vector for 48 h by using Lipofectamine™
2000 transfection reagent (Invitrogen, Carlsbad, CA). Cells were
ﬁxed in 4% paraformaldehyde in PBS for overnight, permeabilized
in 0.2% Triton X-100 for 5 min, and blocked with 1% bovine serum
albumin in PBS for 30 min. Cells were incubated with the respec-
tive primary antibodies for 1 h, washed three times in PBS, and
then incubated with 546-Alexa- (red) or 488-Alexa-labeled (green)
secondary antibodies (Invitrogen, Carlsbad, CA).
2.3. Immunoprecipitation and immunoblotting
Cellular proteins were prepared, separated by 10% SDS–PAGE or
native PAGE and subjected to Western blotting as described
previously [5].
2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated by Total RNA Mini Kit (Geneaid Biotech
Ltd, Taipei, Taiwan) and 1 lg RNA was subjected RT-PCR as
described previously [5]. The primers used for analysis are
RECK-forward: 50-TCTGCAGGGGAAGTTGGTTG-30; RECK-reverse:
50-CAGTTACAGGGCAGACCTGT-30, HER-2/Neu-forward: 50-CCATAA
CACCCACCTCTGCT-30; HER-2/Neu-reverse: 50-ACTGGCTGCAGTTTT
GACACAC-30; VEGF-forward: 50-AAGGAGGAGGGCAGAATCAT-30;
VEGF-reverse: 50-ATCTGCATGGTGATGTTGGA-30; cyclin D1-for-
ward: 50-TCTAAGATGAAGGAGACCATC-30; cyclin D1-reverse
50-GCGGTAGTAGGACAGGAAGTTGTT-30; GAPDH-forward: 50-AAG-
GCTGGGGCTCATTTGC-30 and GAPDH-reverse: 50-GCTGATGATCTT-
GAGGCTGTTG-30.
2.5. Ki-67 staining and cell proliferation assays
Cells were ﬁxed in 4% paraformaldehyde in PBS for overnight,
permeabilized in 0.2% Triton X-100 for 5 min and blocked by 0.5%
H2O2 for 10 min. After blocking, primary antibody (NCL-L-Ki67-
MM1, Nova Castra Laboratories, Newcastle upon Tyne, UK) at
1:200 dilution were incubated for 1 h and the samples were devel-
oped by DAB reagent (Zymed Laboratories, South San Francisco,
CA). For MTT assay, cells were seeded in a 96-well plate with
5000 cells/well. After different times, MTT reagent (Sigma, St. Louis,
MO) was added at a ﬁnal concentration of 5 mg/ml, the plate was
incubated for further 4 h. DMSO was applied to each well, and the
absorbance was determined at 570 nm with a microplate reader.
2.6. Analysis of primary tumor samples
Collection of the breast cancer tissues was approved by the
Medical Ethics and the Human Clinical Trial Committee of
Kaohsiung Medical University Hospital. For the study of patient’s
samples, RECK mRNA level was quantiﬁed by real-time reversetranscription-PCR (RT-PCR) using iQ SYBR Green Supermix (Bio-
Rad Laboratories, Hercules, CA) as described previously [12].
HER-2/Neu staining was collected from routine IHC study after sur-
gery. Clinicopathological data were collected from chart review.
The association between RECK expression and clinicopathological
parameters was studied by Chi Square test. P value less than 0.05
was considered as signiﬁcant.
3. Results and discussions
We ﬁrst ectopically expressed EGFP-tagged HER-2/Neu and His-
tagged RECK protein in 293T cells and detected these two proteins
by indirect ﬂuorescent staining. As shown in Fig. 1A, HER-2/Neu
was mainly localized at plasma membrane. However, we also ob-
served dot-like distribution of this protein. HER-2/Neu has been re-
ported to be concentrated in the lipid raft at plasmamembrane and
the local density of HER-2/Neu inﬂuences its homo- or hetero-
dimerization which plays a critical in the mediation of its oncogenic
activity [13]. Interestingly, we also found a very similar distribu-
tion of RECK protein. After merging, our results suggested that
these two proteins were co-localized at the plasma membrane and
dot-like structure. Analysis of the ﬁgure by Image J software of
NBCI showed partial overlapping of the green (HER-2/Neu protein)
and red (RECK protein) in the histogram proﬁles (data not shown).
However, we observed two interesting ﬁndings. First, the expres-
sion of RECK is always lower than that of HER-2/Neu. These two
expression vectors are driven by CMV promoter and the main host
transcription factor for activating CMV promoter is Sp1. Because
our previous results have shown that HER-2/Neu may repress
RECK via the ERK/Sp1 signaling pathway, it is possible that HER-
2/Neu can compete or interfere CMV-driven RECK expression. An-
other possibility is post-transcriptional regulation. HER-2/Neu has
recently been shown to increase miR-21 expression [14]. Because
RECK is a target gene for miR-21 [15,16], it is reasonable to hypoth-
esize that up-regulation of miR-21 by ectopic expression of HER-2/
Neu in 293T cells may cause reduction of RECK protein level. We
checked the expression of miR-21 in control and HER-2/Neu trans-
fected cells and found a 1.78-fold increase of miR-21 by HER-2/Neu
(Supplementary Fig. 1). Second, the interaction between HER-2/
Neu and RECK is dynamic. In cells co-expressing HER-2/Neu and
RECK, we could detect the co-localization of these two proteins
in 60–70% of cells. This means that we still found a portion of cells
which did not show HER-2/Neu and RECK co-localization although
these two proteins were expressed in the same cell. In addition, the
co-localization areas are variable (from intensively concentrated at
several small areas to extensively overlapped at a number of por-
tions of plasma membrane). These results suggested a dynamic
interaction between HER-2/Neu and RECK. To further approve
the interaction, we performed immunoprecipitation/immunoblot-
ting assay. When EGFP-tagged HER-2/Neu protein was pulled
down from these cells, RECK was found to be co-immunoprecipi-
tated (Fig. 1B). However, we could only pull down small amount
of RECK protein in these experiments because RECK protein level
was low and the interaction between RECK and HER-2/Neu was dy-
namic as found in immunoﬂuorescent staining assay. We next
tried to conﬁrm this conclusion in HER-2/Neu-overexpressing
SKBR3 breast cancer cells. Because SKBR3 cells expressed very
low level of endogenous RECK, we ectopically expressed His-
tagged RECK in these cells to address the interaction of His-tagged
RECK with endogenous HER-2/Neu. Protein distribution of HER-2/
Neu and RECK was very similar to that observed in 293T cells
and was co-localized at plasma membrane and dot-like structure
(Fig. 1C). In addition, His-tagged RECK was also co-immunoprecip-
itated with HER-2/Neu in SKBR3 cells (Fig. 1D). Image analysis also
showed partial overlapping of HER-2/Neu and RECK protein in the
Fig. 1. Co-localization of RECK and HER-2/Neu in cells. (A) 293T cells were transfected with EGFP-tagged HER-2/Neu (H) and His-tagged RECK (R) expression vector for 48 h.
Cells were incubated with the respective primary antibodies for 1 h, and then incubated with 546-Alexa- (red, for RECK) or 488-Alexa-labeled (green, for HER-2/Neu)
secondary antibodies. The nuclei were observed by staining with propidium iodide (PI). (B) The expression of HER-2/Neu and RECK was examined by immunoblotting.
Cellular proteins were also collected by immunoprecipitation (IP) assay and then subjected to immunoblotting (IB) analysis to detect the interaction between HER-2/Neu and
RECK. (C) HER-2/Neu-overexpressing SKBR3 breast cancer cells were transfected with His-tagged RECK and immunoﬂuorescent staining was performed as described above.
(D) The interaction between HER-2/Neu and RECK was examined by co-immunoprecipitation assay.
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shown).These data suggested that RECK may form a complex with
HER-2/Neu.
The effect of RECK on HER-2/Neu signaling was examined. HER-
2/Neu protein was pulled down from SKBR3 cells and receptor-
associated autophosphorylation was detected by anti-phosphoty-
rosine antibody. Our data demonstrated that HER-2/Neu kinase
activity was attenuated by about 40% in RECK-expressing cells
(Fig. 2A). In addition, the downstream AKT and ERK signaling path-
ways were also repressed and ERK was inhibited more signiﬁcantly
than AKT (Fig. 2B). These data suggested RECK may inhibit HER-2/
Neu-mediated oncogenic signaling. Because RECK is a GPI-an-
chored protein and may reduce HER-2/Neu-associated kinase
activity, it is rational to hypothesize that RECK may interfere
HER-2/Neu dimerization which is important for the ligand-
independent trans-autophosphorylation and kinase activation. Ourresults indeed demonstrated that dimerization of HER-2/Neu was
reduced in RECK-expressiing breast cancer cells (Fig. 2C). Because
both HER-2/Neu and RECK are appeared in lipid raft, this may in-
crease the local density of these two proteins and enhance their
interaction. Although HER-2/Neu and RECK can be co-immunopre-
cipitated in different cell lines, whether RECK directly binds to
HER-2/Neu is still unclear at present. Previous studies demon-
strated that extracellular domain of HER-2/Neu is sufﬁcient for
receptor dimerization [17]. In addition, subsequent evidence sug-
gested that subdomain IV of the extracellular domain is important
for dimerization and small peptides with cysteine knot topology is
able to block dimer formation of HER-2/Neu [18]. RECK protein
contains ﬁve putative cysteine knot motifs at the NH2-terminal re-
gion [1]. Therefore, RECK may use this region to interfere HER-2/
Neu dimer formation. Recently, development of HER-2/Neu dimer-
ization inhibitors is an intensive area in cancer treatment. For
Fig. 2. Inhibition of HER-2/Neu signaling by RECK. (A) SKBR3 cells were transfected
with control (C) or RECK (R) vector for 48 h. HER-2/Neu proteins were pulled down
by immunoprecipitation (IP) and the tyrosine phosphorylation status was detected
by immunoblotting (IB) by the PY20 antibody. The signal intensity of phospho-
tyrosine was normalized to HER-2/Neu signal intensity and the ratio was shown. (B)
ERK and AKT activity of SKBR3 cells transfected with control (C) or RECK (R) vector
were also studied by detecting the phosphorylation status of these two kinases (p-
AKT and p-ERK). (C) Cellular proteins were prepared in sample buffer without SDS
and resolved by a native PAGE. After transferring proteins from the native PAGE to
nitrocellulose membrane, the blot was probed with anti-HER-2/Neu antibody.
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which binds the extracellular domain, effectively inhibits HER-2/
Neu homo- or hetero-dimerization, is now undergoing for PhaseFig. 3. Repression of HER-2/Neu target genes and cell proliferation by RECK. (A) SKBR3
isolated and RT-PCR was performed to check the expression of HER-2/Neu target genes
studied by Western blotting. (C) The percentages of Ki-67-positive cells from three i
was performed to monitor cell growth of SKBR3 cells transfected with control (N) or REIII and II clinical trails for the treatment of breast and ovarian can-
cer, respectively [19]. The elucidation of the underlying mecha-
nism by which RECK inhibits HER-2/Neu dimer formation may
lead to the development of a new novel class of anti-cancer drugs.
Because HER-2/Neu signaling was inhibited by RECK, we
hypothesized that HER-2/Neu-induced gene expression should
also be repressed. Three target genes involved in the proliferation
(cyclin D1), angiogenesis (vascular endothelial growth factor,
VEGF) and metastasis (matrix metalloproteinase-9, MMP-9) were
studied. Indeed, mRNA and protein levels of these three genes were
reduced in RECK- expressing SKBR3 cells (Fig. 3A and B). Since cy-
clin D1 was attenuated, we studied whether cell proliferation was
inhibited. The percentage of Ki-67-positive cells of control group
was 47% while it reduced to 30% in RECK-expressing group
(Fig. 3C). MTT assay also demonstrated that the proliferation rate
of RECK-expressing SKBR cells was slower than that of control
group (Fig. 3D). Taken together, our data suggested that interfer-
ence of HER-2/Neu dimerization by RECK leads to reduction of
HER-2/Neu-stimulated gene expression and proliferation.
RECK was originally identiﬁed as a MMP inhibitor with little
anti-proliferative activity on various tumor-derived cell lines,
including HT1080 (sarcoma), B16 (melanoma), SW48 (colon can-
cer), A549 (lung cancer), HeLa (cervical cancer), and A673 (Ewing
tumor) [1]. However, a recent study demonstrated that knockdown
of RECK in human umbilical vein endothelial cells induced growth
arrest and cellular senescence [20]. The authors showed that RECK
depletion could up-regulate a cyclin-dependent kinase inhibitor
p21 in a b1-integrin-dependnet manner suggesting a cell cycle-
regulatory role of RECK. Indeed, we did not ﬁnd signiﬁcant change
of proliferation in RECK-expressing 293T cells. However, the
growth rate of HER-2/Neu-overexpressing SKBR3 cells was
inhibited by RECK. It is possible that RECK directly or indirectly
complexes with some cell surface molecules (like HER-2/Neu andcells were transfected with control (C) or RECK (R) vector for 48 h. Total RNA was
as described in Section 2. (B) The protein level of cyclin D1, VEGF and MMP-9 was
ndependent experiments were expressed as mean ± S.E. ⁄P < 0.05. (D) MTT assay
CK (j) vector.
Table 1
Association of RECK expression and clinicopathological features in breast cancer.
RECK expression (T/N) P value
Reduced Normal
Histological grade
l 11 8 0.394
ll 27 23
lll 15 6
Stage
0–1 22 22 0.217
2 21 9
3l 10 6
Tumour size
T1 33 26 0.716
T2 17 9
T3 3 2
Lymph node invasion
N0 29 30 0.032
N1 13 3
N2 + N3 11 7
HER-2/Neu
P3+ 16 11 0.963
0-2 37 26
ER
– 39 22 0.158
+ 14 15
PR
– 33 21 0.600
+ 20 16
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manner. One of the critical issues should be concerned in RECK
study is the cell lines used. Many works used NIH/3T3 (mouse
ﬁbroblast) or HT1080 (human sarcoma) cells to address RECK func-
tion. However, whether the biological activities of RECK identiﬁed
in these studies indeed reﬂect that in human cancers, which are
mainly derived from epithelial origin, are questionable. Compari-
son between the results obtained from different cell types will be
helpful for the understanding of RECK function in vivo.
Finally, we studied the association of RECK with clinicopatho-
logical features in 90 breast tumors. HER-2/Neu status was col-
lected from routine IHC study after surgery. RECK expression of
paired adjacent normal and tumor tissues were assessed by quan-
titative RT-PCR. Our results showed that RECK expression is re-
duced in 58.8% (53/90) breast cancer tissues and is associated
with lymph node invasion (P = 0.032, Table 1). This supports the
anti-metastatic role of RECK. Down-regulation of RECK is not cor-
related HER-2/Neu over-expression. Thirty percent (27/90) of cases
exhibit over-expression of HER-2/Neu. Among the 27 cases with
high HER-2/Neu, RECK expression is reduced in 59.3% (16/27). This
ﬁnding is in consistent with our previous results that HER-2/Neu
over-expression inhibits RECK gene transcription [5]. Although
our cell-based study demonstrates the growth-inhibitory function
of RECK, no correlation between RECK and tumor size was found.
This may be due to (1) case number or (2) RECK only affects cancer
cells with speciﬁc genetic de-regulation (like HER-2/Neu over-
expression). However, size of breast tumors with normal RECK
expression (1.83 ± 1.41 cm3) is indeed smaller than that of tumors
with reduced RECK (2.02 ± 1.32 cm3). Taken together, our results
provide the ﬁrst evidence that RECK can negatively regulate onco-
genic activity of HER-2/Neu and may be helpful for the treatment
of HER-2/Neu-overexpressing cancers.
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